In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 226 to 250 of 300

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]	Technology appraisal guidance	TBC
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]	Technology appraisal guidance	TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]	Technology appraisal guidance	TBC
Satralizumab for treating relapsing myelin oligodendrocyte glycoprotein antibody associated disease [GID-TA12471]	Technology appraisal guidance	TBC
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]	Technology appraisal guidance	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]	Technology appraisal guidance	TBC
Secukinumab for treating relapsed polymyalgia rheumatica ID6599	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance	TBC
Semaglutide 7.2 mg dose for managing obesity ID6699	Technology appraisal guidance	TBC
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]	Technology appraisal guidance	7 January 2027
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]	Technology appraisal guidance	10 February 2027
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]	Technology appraisal guidance	13 May 2027
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]	Technology appraisal guidance	TBC
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	12 August 2026
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]	Technology appraisal guidance	21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758]	Technology appraisal guidance	TBC

Results per page

10
25
50
All